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CHAPTER 1
History of the 3Rs in Toxicity
Testing: From Russell and Burch
to 21st Century Toxicology
MARTIN L. STEPHENS*a AND NINA S. MAKb
aCenter for Alternatives to Animal Testing, Johns Hopkins University,
615 N. Wolfe Street, W7032, Baltimore, MD 21205, USA; bAlternatives
Research & Development Foundation, 801 Old York Road, #316,
Jenkintown, PA 19046, USA, Email: nmak@ardf-online.org
*Email: mstephen@jhsph.edu
1.1 Introduction
Toxicity testing is an important part of the process of assessing the hazards,
safety, or risk that chemicals and other substances pose to humans, animals, or
the environment. The early toxicity tests that went on to enter routine use were
developed in the first half of the 20th century. These included the LD50 test for
acute systemic toxicity1 and the Draize test for eye irritancy.2 These procedures
used vertebrate animals as test subjects – typically rodents in the LD50 test and
rabbits in the Draize test.
As the new science of toxicology progressed, it continued to rely heavily on
animals as test subjects. This was due largely to the rise of animal (mostly
rodent) breeding for science in general, the virtual absence of more sophisti-
cated ways of assessing toxicity, and the low status of animals in society.
While animal use in toxicology and the life sciences in general rose over the
course of the early and mid-20th century, two parallel trends emerged. Concern
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for animal welfare was growing, and the life sciences were flourishing, with
dramatic advances in knowledge and technique. It was in this context that the
Universities Federation for Animal Welfare (UFAW), founded in England in
1926, made the fateful decision in the mid-1950s to undertake an ambitious
survey of humane experimental techniques in animal-based experimentation
throughout the life sciences.3 The project culminated in a pioneering book, The
Principles of Humane Experimental Technique (hereinafter ‘‘The Principles’’).4
The book’s authors – scientists William Russell and Rex Burch – proposed
the 3Rs framework for making progress on both scientific and animal welfare
fronts. Specifically, they advocated using scientific ingenuity to replace, reduce,
and refine the use of animals wherever feasible without compromising scientific
rigor. Russell and Burch’s extensive discussion of each of the 3Rs included
numerous and diverse examples of each approach, drawing on their broad
knowledge of the life sciences (and that of the experts they consulted).
‘‘Refinement’’ referred to modifications in procedures that resulted in the
animals experiencing less pain, distress, or discomfort. In discussing refinement,
Russell and Burch considered a wide range of issues, including anesthesia,
analgesia, euthanasia technique, injection sites, use of less sentient species, and
adoption of less intense experimental procedures to induce stress. The scope of
refinement eventually expanded beyond limiting negative effects and came to
include enhancing animal welfare, such as through housing social animals in
groups rather than individually, or enriching their cage environment with ob-
jects such as nesting material.5
‘‘Reduction’’ referred to careful design and analysis of animal-based experi-
ments so that fewer animals could be used. In this context, Russell and Burch
discussed a variety of approaches, such as calculating the minimum group size(s)
needed for a particular experiment, conducting testing sequentially rather than
concurrently to exploit information learned in prior stages, and employing ad-
vanced experimental designs (e.g., blocking) that increased statistical power while
using fewer animals. They also called for increased use of genetically uniform
animals, or the offspring of crosses between two different in-bred lines, as a
means of controlling inter-individual variation. And more generally, they argued
that it is contrary to the spirit of reduction to waste animals on experiments that
are poorly conceived, designed, or statistically analyzed.
Finally, ‘‘replacement’’ referred to ways to avoid using whole, sentient ani-
mals, by the use of: (i) non-animal approaches such as in vitro methods,
microorganisms, ethical human studies, and computer simulation, (ii) experi-
ments using invertebrates, or early stage vertebrate embryos, and (iii) an-
esthetized vertebrates. Over time, use of anesthetized vertebrates has come to be
viewed as refinement rather than replacement.
In the 1960s and 1970s, animal protection organizations began to use the
term ‘‘alternatives’’ for the 3Rs, especially replacement, as part of their chal-
lenge to the status quo. Thus the ‘‘alternatives’’ label proved to be more pol-
itically charged than did the ‘‘3Rs.’’
The forceful championing of alternatives left some scientists uneasy.6






























































W. H. Wiehe argued that ‘‘alternative methods are a fallacy’’ and that in vivo
experiments are ‘‘irreplaceable.’’7 Ironically, a 1978 book by the Research
Defence Society (in England) had explicitly and approvingly used this term
‘‘alternatives’’ to refer to each of the 3Rs in a book entitled ‘‘Alternatives to
Animal Experiments.’’8
Yet a little more than a generation after Wiehe’s dismissive remark, following
the 2007 publication of a US National Research Council (NRC) report on
‘‘Toxicity Testing in the 21st Century, A Vision and a Strategy,’’9 prominent
scientists were predicting the near elimination – if not the total replacement – of
animal use in toxicity testing through the development of ‘‘21st Century Tox-
icology.’’ Melvin Andersen and Daniel Krewski (members of the committee
that drafted the NRC report) noted that the report ‘‘envisions a not-so-distant
future in which virtually all routine toxicity testing would be conducted in
human cells or cell lines in vitro.’’10 Key government scientists in the United
States, led by Francis Collins, currently director of the National Institutes of
Health (NIH), wrote in a 2008 policy forum of the prestigious journal Science
that federal initiatives are ‘‘promoting the evolution of toxicology from a
predominantly observational science at the level of disease-specific models
in vivo to a predominantly predictive science focused on broad inclusion of
target-specific, mechanism-based, biological observations in vitro.’’11 That
same year Collins’ predecessor, Elias Zerhouni, had referred to these initiatives
as the beginning of the end of animal testing.12 In an 2011 editorial about the
efforts of the US Food and Drug Administration (FDA) to modernize regu-
latory science, FDA Commissioner Margaret Hamburg wrote in Science that
the agency is ‘‘working to eventually replace animal testing with a combination
of in silico and in vitro approaches.’’13
How have we gotten from Russell and Burch to the beginnings of 21st
Century Toxicology? That journey will be the focus of this chapter.
1.1.1 Measuring 3Rs Activity: Our Approach
In our effort to trace the path from Russell and Burch to 21st Century Tox-
icology, we compile information on a wide range of 3Rs activities in the field of
toxicology from 1959, when The Principles was published, to the present. In
doing so, we want to supplement a conventional narrative approach to a his-
torical review, which can be subjective in the choice of events and papers
considered – and therefore in the interpretations offered – with more objective
measures.
To that end, we begin with comprehensive citation and literature searches to
trace the influence of Russell and Burch’s 3Rs framework and the prevalence of
3Rs-related research in toxicology over time, as revealed by patterns in the
toxicological literature. When did Russell and Burch’s framework start influ-
encing the field of toxicology? How relevant have the 3Rs been to toxicology
research? These are the kind of questions we sought to answer.
We then present timelines of various 3Rs activities to inform our historical
analysis. These activities include the founding of 3Rs organizations and centers,





























































the establishment of 3Rs funding sources, the enactment of animal welfare/
alternatives laws, the founding of 3Rs journals and websites, the occurrence of
3Rs workshops and conferences, and other milestones.
Following this, we integrate the findings from the literature searches and
timelines to briefly tell the story of the 3Rs in toxicology, framing the narrative
around what we regard as four phases of activity:
 incubation (1959–1979),
 increasing acceptance and spread (1980–early 1990s),
 maturation (early 1990s–2007), and
 paradigm shift (2007–present).
We then look at measures of the impact of this 3Rs activity on toxicity
testing, focusing on alternative methods that have been successfully validated
and accepted for regulatory use and any impact of these methods on trends in
animal use. We conclude with a section on remaining challenges to replacing
animal use in toxicology.
A number of narrative histories of the 3Rs in toxicology or in the life sciences
generally have been written previously.14–17 Similarly, although not necessarily
focused on toxicology, a number of reviews have been written regarding re-
finement,18–20 reduction,21–23 and replacement,24–27 separately or in combin-
ations.28,29 In our survey, we bring some of these earlier reviews up-to-date,
focusing exclusively on toxicology and treating the 3Rs as a holistic framework,
rather than covering each R thematically. We also explore literature searches as
a source of additional historical insight and attempt to objectively assess the
impact of the past 50-plus years of 3Rs activity in toxicology.
1.2 3Rs-Related Trends in the Toxicological Literature
Citation and literature searches can reveal historical patterns in the uptake and
prevalence of 3Rs-related research in toxicology. To our knowledge, this ap-
proach has not been thoroughly investigated before. Some noteworthy findings
are discussed here, and are incorporated in our discussion of historical phases
of 3Rs activity (Section 1.4).
Our searches were designed specifically to capture toxicology-related papers
that: (i) cite the book that launched the 3Rs framework (The Principles, both
the 1959 original and a 1992 reprinting30), (ii) cite the NRC report that pro-
posed a paradigm shift to non-animal-based toxicity testing (Toxicity Testing in
the 21st Century), and (iii) explicitly address one or more of the 3Rs or alter-
natives, based on the presence of selected 3Rs terminology, synonymous
phrases, or database indexing terms. This last set of papers was further ana-
lyzed to explore the prevalence of key 3Rs topics, such as validation of new
methods, based on the inclusion of relevant terminology in the paper’s title,































































An analysis of citations in the toxicological literature to Russell and Burch’s
pioneering book and the NRC’s seminal report is perhaps the most direct as-
sessment of the influence of these works over time and the extent of discussion
about the ideas they espoused. The literature searches for 3Rs-related publi-
cations, meanwhile, give a sense of the prevalence of ‘‘alternatives’’ work de-
voted to investigating, considering, or applying 3Rs concepts within the field of
toxicology over the past 50-plus years, irrespective of whether or not Russell
and Burch or Toxicity Testing in the 21st Century were explicitly cited.
According to our results, from 1959, when Russell and Burch’s The Prin-
ciples was first published, to 2011, the last year for which we have complete
data, 438 publications in the toxicology/pharmacology literature cited their
work.a The search for toxicological papers addressing one or more of the 3Rs
yielded nearly 3200 publications.
These findings indicate that far more papers discussed or applied replace-
ment, reduction, refinement, or alternatives concepts than cited Russell and
Burch’s pioneering book. Perhaps one reason for this discrepancy, at least in
recent years, is that authors take the 3Rs framework as a given, without the
perceived need to reference its origin. As the 3Rs framework becomes in-
creasingly integrated into toxicity testing programs and animal research pol-
icies (e.g., via the REACH program in Europe31), these efforts may act as other,
more recent drivers for authors considering the question.
Notwithstanding the discrepancy in absolute numbers, the historical trend in
toxicological publications citing The Principles (Figure 1.1) is similar to those
addressing one or more of the 3Rs (Figure 1.2). There was a clear initial period
of relative dormancy following publication of The Principles in 1959, lasting
until the early 1980s, as revealed by the relative dearth of publications citing
Russell and Burch or addressing the 3Rs. Citations and 3Rs papers began
appearing regularly around 1980, with a fairly steady growth starting in the
1990s and a sharp uptick after 2007.
The dip in citations to The Principles starting in 2000 (Figure 1.1) is possibly
an artifact of our search strategy, as we had augmented our search with two
additional databases for the years prior to 2000 (see Appendix A for details).
Removing the citations unique to those extra databases produces a more
consistent upward trend (data not shown).
Parsing our universe of 3Rs-related papers from Figure 1.2 reveals finer-
grained trends in the 3Rs literature. Figure 1.3, for example, shows that in the
earlier years, a far greater percentage of 3Rs papers mentioned reduction (in the
title, abstract, or keywords) than either refinement or replacement. This is
surprising in that much of the reduction literature is generic – not specifically
focused on toxicology or any other particular discipline. We suspect that some
of these early toxicology papers were using ‘‘reduction’’ loosely to refer to di-
minishing animal use through either replacement or reduction.
aWe emphasize that this represents just some of all the citations to Russell and Burch’s book
throughout the scientific literature during this period.





























































Over time, however, refinement and replacement papers became more
prevalent, narrowing the gap between reduction papers on the one hand and
refinement and replacement papers on the other. By 2011, approximately 40%
of the papers we examined were related to reduction, 30% to replacement, and
20% to refinement. Removing those papers that mention all three Rs from the
analysis does little to change this trend (data not shown). Similarly, inclusion of
those papers found in the database searches using synonyms of ‘‘reduction’’ or
‘‘refinement’’ (e.g., ‘‘decreased use of animals,’’ ‘‘lessen pain,’’ etc.) does not
substantively change the results, probably because these represent a very small
percentage of papers in a given year (data not shown). (No searches were
conducted using synonyms of ‘‘replacement.’’)
Interestingly, papers that did not explicitly mention any of the 3Rs
(replacement, reduction, or refinement) typically constituted the majority until
the early 2000s. These papers were likely identified during our literature search
Figure 1.1 Citations to Russell and Burch’s The Principles of Humane Experimental
Technique (1959 and 1992 editions) by year (1959–2011), as identified by
citation searches of Web of Science, BIOSIS, and SCOPUS databases
through 2011, as well as SciSearch and Google Scholar databases through
1999, limited to the toxicological or pharmacological literature.
Figure 1.2 Publications related to the 3Rs and alternatives by year (1976–2011), as
identified by literature searches using Embase and Ovid Medline databases






























































owing to their use of the more general term ‘‘alternative’’ or ‘‘3Rs,’’ rather than
a specific R term. During the 2000s, papers not mentioning any R became less
frequent, and these papers made up an almost equal percentage as reduction
papers by 2011.
Looking at our universe of 3Rs-related toxicology papers from Figure 1.2 in
a different way, we determined the frequency with which certain key topics
appeared in this collection. We made no attempt to be exhaustive, although we
did choose a representative sampling of alternatives-related topics. These were
as follows:
 ‘‘In vitro,’’ ‘‘cell culture,’’ and/or ‘‘tissue culture’’: these terms broadly
represent the most commonly used type of non-animal testing.
 ‘‘In silico’’ and/or ‘‘SAR’’ (Structure–Activity Relationships): these
computer-based methods, including (Quantitative) Structure–Activity
Relationships, generate toxicological predictions based on chemical
properties.
 ‘‘Validation’’: this is the process by which the relevance and reliability of
methods are assessed for a particular purpose (see also Section 1.5.1).
These are formal assessments of whether test methods (often new alter-
native methods) are fit for purpose and ready for consideration to be in-
cluded in regulatory toxicology.
 ‘‘Testing strategies’’: these are frameworks incorporating two or more
types of testing. Commonly known as ‘‘integrated’’ or ‘‘intelligent’’ testing
strategies, these efforts are often employed as a means of increasing testing
efficiency and thereby limiting animal testing.
 ‘‘Humane endpoint’’: a type of refinement in which an experiment is ter-
minated at an earlier point, sparing animals unnecessary suffering without
loss of experimental information.32
Figure 1.3 Percentage of 3Rs-related publications of those identified in Figure 1.2
mentioning ‘‘replac’’ (Replacement), ‘‘reduc’’ (Reduction), or ‘‘refin’’ (Re-
finement) in their title, abstract, or keywords (1983–2011). Some papers fall
under multiple categories if they have multiple R terms. ‘‘No R’’ refers to
those papers that have none of the R terms in the title, abstract, or key-
words (e.g., papers that use the term ‘‘alternative’’ or ‘‘3Rs’’ instead).





























































 ‘‘Enrichment’’: a type of refinement in which an animal’s living situation is
enhanced through various means, including the provision of a social
partner, nesting material, or food puzzles.33
Papers mentioning ‘‘in vitro,’’ ‘‘cell culture,’’ and/or ‘‘tissue culture’’ in the
title, abstract, or keywords consistently constituted 30–50% of the 3Rs papers
over time (Figure 1.4). Other topics, such as ‘‘in silico’’ and/or ‘‘SAR’’ and, to a
greater degree, ‘‘validation,’’ rose in prominence over the years. ‘‘Validation’’
represented a quarter to a third of the 3Rs papers most years from 1993–2011.
The concept of (integrated) testing strategies first appeared in this literature in
1990 and increased noticeably in the 2000s. Other topics, such as ‘‘humane
endpoint’’ and ‘‘enrichment’’ have a recent but minor presence in the 3Rs lit-
erature in toxicology.
Another important topic relevant to the history of the 3Rs in toxicology is
‘‘21st century toxicology’’ as exemplified in the 2007 NRC report on Toxicity
Testing in the 21st Century (see also Sections 1.1, 1.3, and 1.4.4). This report
has considerable relevance to replacement in toxicology. Interestingly, it was
not the output of the 3Rs community per se but it was clearly the product of an
era informed by Russell and Burch and the 3Rs approach, as well as by a
broader concern for animal welfare and an appreciation for how far science and
technology had advanced since the early days of animal testing.34 We con-
ducted a separate citation analysis on this report. From 2007, when Toxicity
Testing in the 21st Century was published, to 2011, we identified 216 citations to
it, indicating that the report has generated extensive discussion and imple-
mentation during the few years since its publication. Perhaps tellingly, citations
to the report in the last two years have surpassed those to The Principles
(Figure 1.5), and preliminary data indicate that the same is likely to be true
in 2012.
Figure 1.4 Percentage of 3Rs-related publications of those identified in Figure 1.2
mentioning select key topic phrases in their title, abstract, or keywords
(1983–2011). Variants of key phrases were included when applicable, e.g.,
‘‘validat’’ for Validation; ‘‘SAR,’’ ‘‘structure activity relation,’’ or































































Our citation and literature searches provide insights regarding the influence
of Russell and Burch and their 3Rs framework in toxicology, but they cannot
be expected to reveal the whole story. For one thing, while our searches were
comprehensive, they were not exhaustive. This, combined with other limi-
tations in database searching, means we have likely underestimated the abso-
lute number of citations and 3Rs papers. (For further discussion of the
limitations of our approach, see Appendices A and B.)
In addition, our searches do not capture the 3Rs work done outside the field
of toxicology but that has nevertheless influenced the work of toxicologists.
During the early 1980s, for example, the work of Russell and Burch figured into
more general questions of animal use, when papers related to the ethics and
necessity of animal experimentation cropped up as the U.S. Congress debated
and ultimately passed significant amendments to the Animal Welfare Act
dealing with animals in research.
Many refinement and reduction papers have also been framed generally,
rather than narrowly tailored to toxicology. ‘‘Humane endpoints’’ has been a
hot topic in refinement for years, but is barely present in the toxicological lit-
erature. Toxicologists likely reference and make use of these sorts of papers,
even if they are not indexed as toxicology papers.
1.3 Timelines of 3Rs Activities in Toxicology
Timelines can provide an event-based view of the development of the 3Rs in
toxicology over time. We compiled 3Rs timelines that update those published
previously14–16 and focus them primarily on toxicology. We also group events
according to activity type rather than by time blocks to allow for an additional
level of analysis. Unlike the literature searches in Section 1.2, the timelines are
largely self-explanatory, so we simply provide an annotated list of them here as
a prelude to weaving them into our discussion of historical phases of 3Rs ac-
tivity in Section 1.4.
Figure 1.5 Citations to the National Research Council’s Toxicity Testing in the 21st
Century: A Vision and a Strategy (2007) by year (2007–2011), as identified
by citation searches of Web of Science, BIOSIS, and SCOPUS databases
through 2011 and limited to the toxicological and pharmacological litera-
ture, alongside citations to Russell and Burch’s The Principles of Humane
Experimental Technique from 2007–2011 (see Figure 1.1).





























































Our timelines are organized into the following activity types:
 Early funding sources (Table 1.1): the establishment of funding sources for
‘‘humane research,’’ which began in the 1960s, was one of the earliest
manifestations of the impulse to promote alternatives research.
 Early animal welfare/alternative laws (Table 1.2): countries incorporated
the 3Rs in their legislation beginning in the late 1970s.
Table 1.1 The establishment of some early funding sources for 3Rs research.







UK The first research






























Germany A biennial award of

































































































 Journals and websites (Table 1.3): several journals and websites devoted to
alternative methods were founded, beginning in the early 1970s.
 Early workshops and conferences (Table 1.4): several conferences devoted
to alternative methods were organized beginning in the mid-1970s, in-
cluding ones that became part of a series, such as the Center for Alter-
natives to Animal Testing (CAAT) symposia, as well as the ongoing Linz
conferences and World Congresses on Alternatives and Animal Use in the
Life Sciences.
 Alternatives organizations and centers (Table 1.5): an impressive number of
organizations and centers dedicated to the 3Rs were founded over the
years. Among the most prominent are the Fund for the Replacement of
Animals in Medical Experiments or FRAME (1969), CAAT (1981),
Table 1.2 The enactment of representative alternatives-related laws.
Year Event Country Note
1977 Animal Protection Law
includes a section on
alternatives





















1986 Laws requiring consideration
of alternatives in animal
research
Germany
1992 Cosmetic Directive bans
marketing of cosmetics tested
on animals after Jan. 1, 1998




1994 The 1993 National Institutes of
Health Revitalization Act
leads to the establishment of
ICCVAM
United States
2000 ICCVAM Authorization Act United States Strengthened
ICCVAM’s status
and mandate








Abbreviations: ICCVAM: Interagency Coordinating Committee on the Validation of Alternative
Methods; REACH: Registration, Evaluation, Authorisation and Restriction of Chemicals.
Source: Ref. 16.





























































Center of the Documentation and Evaluation of Alternative Methods to
Animal Experimentation [better known by its German acronym, ZEBET]
(1989), European Centre for Alternatives to Animal Methods or ECVAM
(1992), the US-based Interagency Coordinating Committee on the Val-
idation of Alternative Methods or ICCVAM (1994), and Japanese Center
of the Validation of Alternative Methods or JaCVAM (2005).
 Developments related to pathway-based testing (Table 1.6): the publication
of the US NRC report in 2007 on Toxicity Testing in the 21st Century, A
Vision and a Strategy9 revolutionized thinking about the future of toxicity
testing (see also Sections 1.1, 1.2, and 1.4.4). Its emphasis on upstream,
pathway-based testing has led to – or provided intellectual backing for – a
number of important efforts with dramatic implications for replacing
animal use in toxicology, including the U.S. Environmental Protection
Agency’s ToxCast program and the multi-agency Tox21 program.
These timelines depict representative events and are not necessarily
exhaustive. Particular attention was paid to early developments; for some
Table 1.3 The founding of some representative journals and websites devoted
to the 3Rs or non-animal methods.











1984 The journal ALTEX,



























1996 Altweb, a website
devoted to the















































































activities, recent developments were too numerous to be included in their
entirety.
1.4 Phases in the History of the 3Rs in Toxicology
Taking together the results of our literature searches (introduced in Section 1.2)
and our timelines of important events (introduced in Section 1.3), we find it
helpful to view the history of the 3Rs from Russell and Burch to 21st Century
Toxicology as a progression through four phases: incubation, increasing ac-
ceptance, maturation, and paradigm shift. We divide the following historical
narrative into these (somewhat overlapping) phases simply as a heuristic device
to aid interpretation and understanding. We do not intend the phases to be
Table 1.4 Representative early workshops and conferences on the 3Rs and
alternatives.
Year Event Note Source
1975 The National Academy




Topic: ‘‘The Future of
Animals, Cells, Models,













1982 CAAT’s first symposium Center for Alternatives to
Animal Testing
Ref. 14














applying in vitro methods
Ref. 14














1993 The first World Congress
on Alternatives and
Animal Use
Subsequent WCs held in
1996, 1999, 2002, 2005,
2007, 2009, and 2011.
Ref. 58








Abbreviations: CAAT: Center for Alternatives to Animal Testing; FRAME: Fund for the Re-
placement of Animals in Medical Experiments; MEGAT:Middle European Society for Alternatives
to Animal Testing; EUSAAT: the European Society for Alternatives to Animal Testing; OECD:
Organisation for Economic Co-operation and Development.





























































Table 1.5 The founding of representative alternatives organizations and centers.
Year Event Country Source
1969 Fund for the Replacement of Animals in Medical
Experiments (FRAME)
United Kingdom http://www.frame.org.uk
1981 Center for Alternatives to Animal Testing
(CAAT)
United States http://caat.jhsph.edu
1985 The European Research Group into Alternatives
to Toxicity Testing (ERGATT)
Europe




1986 Foundation for the Promotion of Alternate and




1987 3R Research Foundation Switzerland http://www.forschung3r.ch/index_en.html
1989 Center for the Documentation and Evaluation of
Alternative Methods to Animal
Experimentation (ZEBET)
Germany http://www.bfr.bund.de/en/zebet-58194.html




1994 Interagency Coordinating Committee on the
Validation of Alternative Methods (ICCVAM)
United States http://iccvam.niehs.nih.gov
1994 Netherlands Centre for Alternatives to Animal
Use (NCA), now National Knowledge Centre on
Alternatives (NKCA)
Netherlands http://www.nca-nl.org
1996 Prince Laurent Foundation Belgium http://www.fondation-prince-laurent.be
1997 Institute for In Vitro Sciences (IIVS) United States http://www.iivs.org








































































2000 European Consensus Platform for Alternatives
(ECOPA)
Europe http://www.ecopa.eu
2004 National Centre for the Replacement, Refinement
and Reduction of Animals in Research (NC3Rs)
United Kingdom http://www.nc3rs.org.uk




2005 European Partnership for Alternative Approaches
to Animal Testing (EPAA)
Europe http://ec.europa.eu/enterprise/epaa/index_
en.htm
2005 Japanese Center for the Validation of Alternative
Methods (JaCVAM)
Japan http://jacvam.jp/en/
2007 Norwegian Consensus Platform for Replacement,
Reduction and Refinement of Animal
Experiments (Norecopa)
Norway http://www.norecopa.no
2007 French Platform for the Development of
Alternative Methods in Animal Testing
(FRANCOPA)
France http://www.francopa.fr
2007 Centre for Advanced Research & Development of
Alternative Methods (CARDAM)
Belgium http://www.cardam.eu/
2008 Finnish Centre for Alternative Methods (FICAM) Finland http://ficam.fi
2009 Center for Alternatives to Animal Testing
(CAAT) – Europe
Germany http://cms.uni-konstanz.de/leist/caat-europe/
2010 South Korean Centre for the Validation of
Alternative Methods (KoCVAM)
South Korea http://ihcp.jrc.ec.europa.eu/glossary/kocvam
2010 American Society for Cellular and Computational
Toxicology (ASCCT)
United States http://ascctox.org/index.cfm





















































































Table 1.6 Representative developments related to pathway-based testing as exemplified by the National Research Council
report on Toxicity Testing in the 21st Century.
Year Event Note Source
2007 Toxicity Testing in the 21st Century:
A Vision and a Strategy published
A US National Research Council
report commissioned by the US EPA
http://www.nap.edu/
openbook.php?record_id¼ 11970
2007 US government launches Tox21
program, including the EPA
component, ToxCast




2010 Human Toxicology Project
Consortium holds a conference on
accelerating the transition to
pathway-based testing




2010 AXLR8 established Coordinates R&D to accelerate the
transition to pathway-based testing
http://axlr8.eu





2011 Human Toxome Project established
at CAAT
Mapping pathways of toxicity http://www.altex.ch/en/
index.html?id¼ 50&iid¼ 123&aid¼ 1
2012 The Hamner Institutes for Health
Sciences begins case study
approaches to implementing the
NRC vision
Designing pathway assays for use in
risk assessment
http://www.thehamner.org
2012 OECD establishes Adverse Outcome
Pathways (AOPs) as a basic
principle of the Test Guidelines
Programme
Issues Draft Guidance: Proposal for a
Template and Guidance on








































































taken too literally or to represent the only meaningful way to designate eras
within this history.
1.4.1 Incubation (1959–1979)
As noted in Section 1.2, there is a clear time-lag between the publication of The
Principles in 1959 and the emergence of publications in the toxicological lit-
erature that either cite this book (Figure 1.1) or mention the 3Rs concepts it
described (Figure 1.2). This delayed uptake is consistent with the relative
paucity of noteworthy events during this period, as revealed by the timelines
(Section 1.3). Nonetheless, the main and enduring events during this phase
were: (1) the establishment of several early funding sources for 3Rs research,
the first of which was the (British) Humane Research Trust (Table 1.1), and (2)
the founding of the alternatives center FRAME (Table 1.5) and its journal
ATLA (Table 1.3). These early events occurred primarily in Great Britain,
fittingly the home country of Russell and Burch and UFAW – the organization
that launched their project.
These findings are consistent with the common understanding that, for
toxicology and the life sciences in general, Russell and Burch figuratively
wandered in the wilderness for decades before their book got the attention it
deserved.14,16,35 In hindsight, there are perhaps many reasons for this. For
example, after the book was published, William Russell, Rex Burch, and
UFAW each quickly moved on to other challenges, largely leaving it to others
to take up the ideas in the book.
Another possible reason for the lag in attention to The Principles and its 3Rs
framework in toxicology may have been the early appearance of the book
relative to the emergence of the field of toxicology as a scientific discipline. The
Principles was published in 1959 before toxicological societies had even been
established in the United States (1961) and Britain (1979). It also appeared
early in the history of laboratory animal science, the discipline that emerged to
address issues related to the care, management, and use of laboratory animals.
In the United States, the first Guide for the Care and Use of Laboratory
Animals was not published until 1963.b
1.4.2 Increasing Acceptance and Spread (1980–early 1990s)
A second phase in the history of 3Rs activity in toxicology, roughly from 1980
through the early 1990s, is characterized by rising attention to the 3Rs, as
evidenced both by increasing reference to The Principles (Figure 1.1), a greater
number of 3Rs-related publications (Figure 1.2), and a clustering of notable
developments.
Specifically, what we are characterizing as the increasing acceptance and
spread of the 3Rs approach in Europe and North America are variously re-
flected in the establishment of alternatives centers such as CAAT and ZEBET
bhttp://www.aalas.org/association/history.aspx#Timeline





























































(Table 1.5), the incorporation of the 3Rs framework in legislation such as the
European Union legislation governing animal experimentation (EC 86/609)
(Table 1.2), the founding of journals such as ALTEX dedicated to the subject
(Table 1.3), and the organization of conferences such as FRAME’s ‘‘Animals
and Alternatives in Toxicity Testing’’ conference and a series of conferences
organized by CAAT, each of which resulted in an edited volume of proceedings
(Table 1.4).36 In the United States, another noteworthy milestone in the in-
creasing acceptance of the 3Rs approach was the 1986 publication of the
Congressional Office of Technology Assessment’s lengthy report on Alter-
natives to Animal Use in Research, Testing, and Education, which included two
chapters on toxicity testing.37
A key driver of the increasing acceptance of the alternatives approach, es-
pecially in toxicology, was the emergence of the animal rights movement and its
criticism of animal experimentation, particularly procedures such as the Draize
eye irritancy test that were used to assess cosmetics and other consumer
products.6 In the United States, such criticism led Revlon to fund an alter-
natives research program at Rockefeller University and the Cosmetics Toile-
tries and Fragrance Association to establish CAAT.38 Animal advocacy also
led to a general expansion of funding sources for alternative methods, and
helped to create the political climate that led to the incorporation of alter-
natives provisions in federal legislation such as the Animal Welfare Act and the
ICCVAM Authorization Act (Table 1.2).
1.4.3 Maturation (early 1990s–2007)
A third phase in the history of 3Rs activity in toxicology, from roughly the
early 1990s until 2007, was one of maturation of the field, characterized by
continuing growth in publication of 3Rs papers (Figure 1.2) and citations to
The Principles (Figure 1.1), and the founding of over a dozen alternatives
centers (Table 1.5). Also noteworthy was the considerable activity around
validation principles and processes (see also Section 1.5.1), with the emergence
of national or regional validation centers in the European Union, the United
States, and Asia (Table 1.5). Not surprisingly, then, the topic of validation was
also increasingly prominent in the 3Rs literature (Figure 1.4), and dozens of
alternative tests were validated (see Section 1.5.1), thanks in part to the work of
ZEBET, ECVAM, ICCVAM, and JaCVAM.
During this period, the aim of one-to-one replacement of an animal test with
an alternative test began to slowly give way to an appreciation of the value of
integrated testing strategies, especially for challenging endpoints such as eye
irritation and chronic systemic toxicity. This transition is reflected in the in-
creasing representation of (integrated) testing strategy papers in the 3Rs lit-
erature (Figure 1.4). Nonetheless, the historical animal tests were, by and large,
still assumed to represent the benchmark against which the performance of
alternative tests and strategies were to be judged.
Given that 3Rs work was becoming increasingly international, the organ-






























































Sciences was a notable early event of this period. While the first major meetings
on alternative methods began in the 1970s (Table 1.4), it was the World
Congresses, initiated in 1993 by CAAT and reconvened every 2–3 years to the
present, that gave those committed to the 3Rs a sense of community. Those
meetings, which are devoted in large measure to toxicology issues, have drawn
several hundred to over one thousand participants – scientists, administrators,
regulators, funders, or animal advocates – from dozens of countries, and have
been held in Europe, North America, and Asia.
International efforts on alternative methods have also been furthered by the
work of the Organisation for Economic Co-operation and Development
(OECD), an economic alliance of over 30 developed countries. These countries
participate in the OECD’s influential test guidelines program, which issues
harmonized test guidelines and guidance documents, develops and validates
test methods, coordinates testing programs, and encourages mutual acceptance
of data generated using its approved guidelines.c
1.4.4 Paradigm Shift (2007–present)
In many respects we are still in the maturation phase. However, a tipping point
was reached in 2007 that leads us to designate a fourth (and current) era, one of a
paradigm shift. The precipitating event was the publication of the NRC report
on Toxicity Testing in the 21st Century: A Vision and a Strategy (Table 1.6; see
also Sections 1.1 to 1.3). This report, commissioned by the U.S. EPA, gave us the
phrase ‘‘21st Century Toxicology’’ with its emphasis on testing that is in vitro,
focused largely on human biology, based on upstream biological pathways and
perturbations to normal processes, often characterized using high-throughput
methodology and supplemented with computational approaches.
In this framework, the focus is no longer on predicting apical endpoints in
high-dose animal studies, such as tumors or death. Rather, the NRC report
proposes developing assays that detect perturbations to fundamental biological
pathways (e.g., DNA synthesis and repair) that would typically lead to adverse
phenotypic outcomes. Precise predictions of those outcomes would be sec-
ondary to identifying upstream perturbations to be avoided. The NRC vision
was proposed as a long-term transformation, and in the early years, any
pathway-based testing would need to be heavily complemented by ‘‘targeted
testing,’’ which would be mostly in vivo. Even such supplemental testing could
move towards in vitro systems – in this case systems of a more complex and
integrated nature (e.g., ‘‘organs on a chip’’) - prior to the envisioned complete
(or near complete) transition to pathway-based testing.
The proposed pathway-based framework was not the work product of the
mainstream 3Rs community, although one of the charges to the NRC com-
mittee that developed the proposal was to consider ways to reduce animal
testing, which itself is a reflection of the penetration of 3Rs/animal welfare ideas
throughout the toxicology community. Not surprisingly, the proposal has been
chttp://www.oecd.org/env/ehs/testing/





























































embraced by the 3Rs community and seen as consistent with earlier calls for
in vitro approaches and criticisms of animal testing.34,39
Toxicity Testing in the 21st Century gained immediate recognition in the
toxicological literature (Figure 1.5). Interestingly, citations to the report sur-
passed citations to The Principles in 2010 and 2011. The report perhaps also
spurred the significant uptick in 3Rs-related toxicology papers since 2007.
A number of efforts have emerged seeking to promote ‘‘21st century,’’
pathway-based testing (Table 1.6). These include research and development
programs on a large-scale in the United States (ToxCast and Tox21) and in the
EU (e.g., SEURAT) and smaller scale efforts led by CAAT and the Hamner
Institutes for Health Sciences. On the policy level, the Human Toxicology
Project Consortium in the United States and the AXLR8 project in the
European Union have sought to promote 21st century toxicology by assessing
gaps in current R&D efforts and spurring needed efforts.
1.5 Impact Assessment of 3Rs Activity
To this point in the analysis, we have looked at the history of 3Rs activity in
toxicology as revealed by patterns in the toxicological literature and by various
timelines. So what difference has all this activity made in regulatory toxicity
testing? We will examine this from two perspectives.
First, we look at alternative tests that have successfully gone through the
process of validation and regulatory acceptance. Second, we assess whether
these successes have had any discernible impact on overall trends in the use of
animals in toxicology.
1.5.1 Validation and Acceptance Status of Alternatives
In vitro and other alternative tests have a long history of use in corporate
decision-making about chemical safety and product formulation.40 However, for
many years such testing was not necessarily considered definitive in the regu-
latory context. Corporations would often follow up on their alternative testing
with the historical animal-based methods. Validation – the formal assessment of
the relevance and reliability of a test method for a particular purpose41 – came to
be considered a prerequisite for regulatory use of alternatives.42
Moreover, validation needed to be followed by a declaration of regulatory
acceptance by the relevant government agencies, as a way of encouraging in-
dustry to use the validated tests and submit data based on them. Indeed, the
need for successful validation and regulatory acceptance are written into U.S.
law through the ICCVAM Authorization Act of 2000.d
New and modified assays that have been validated and accepted for regu-
latory use are listed in Table 1.7. A number of patterns can be discerned. First,
most of the assessments of validation status and regulatory acceptance have































































Table 1.7 Alternative test methods and testing strategies: Their validation and regulatory acceptance status.
Full (O) or
Partial (O*)
Replacementa Reduction Refinement Validation Status Regulatory Acceptance
Aquatic Toxicity
Upper threshold concentration step-down
approach
O 2006 (ESAC) 2010 (OECD)b
Acute Systemic Toxicity (Oral)
Up-and-down procedure O 2001 (ICCVAM) 2006 (OECD)
Normal human keratinocyte neutral red
uptake (NHK NRU) assay
O* 2006 (ICCVAM) 2010 (OECD)
Balb/c 3T3 NRU assay O* 2006 (ICCVAM) 2010 (OECD)
Acute toxic class method O 2007 (ESAC) 2001 (OECD)
Fixed dose procedure O O 2007 (ESAC) 2001 (OECD)
Acute Systemic Toxicity (Inhalation)
Acute toxic class method O 2009 (OECD)
Fixed concentration procedure O O draft (OECD)
Carcinogenicity (Non-genotoxicity)
Cell transformation assays O* 2012 (ECVAM) draft (OECD)
Chronic Toxicity
Removal of 1 year dog study for pesticides O 2006 (ESAC) Revised US EPA Pesticide
Data Requirements
Dermal Penetration
In vitro skin absorption methods O*c 2002 (OECD) 2004 (OECD)
Endocrine Active Substances
Androgen receptor binding assay
(rat prostate cytosol)
Ex vivo* 2009 (EPA)




transcriptional activation assay for
estrogen agonists (STTA)




















































































Replacementa Reduction Refinement Validation Status Regulatory Acceptance
Estrogen receptor binding assay rat uterine
cytosol (ER-RUC)
O*(Ex vivo) 2009 (EPA)
H295R steroidogenesis assay O* OECD/EPA 2009 (EPA), 2011 (OECD)
US EPA Tier 1 Screening Battery O* O 2009 (EPA)
BG1Luc ER TA test method for estrogen
agonists and antagonists
O* 2012 (ICCVAM) draft (OECD)
Eye Corrosion
Bovine corneal opacity permeability
(BCOP) test
O* 2007 (ICCVAM) 2009 (OECD)
Isolated chicken eye (ICE) test O* 2007 (ICCVAM) 2009 (OECD)
Cytosensor Microphysiometer modified
(cytotoxicity/cell-based assay)
O* 2009 (ESAC) 2010 (draft OECD)
Fluorescein Leakage (cytotoxicity/cell-
based assay)
O* 2009 (ESAC) 2010 (draft OECD)










Routine use of topical anesthetics,
systemic analgesics, and humane
endpoints
O 2009 (ICCVAM) draft (OECD)
Eye Irritation
Cytosensor Microphysiometer modified
(cytotoxicity/cell-function based in vitro
assay)
O* 2009 (ESAC) 2010 (OECD draft)





































































Routine use of topical anesthetics,
systemic analgesics, and humane
endpoints
O 2009 (ICCVAM) 2012 (Expected)
Genotoxicity
In vitro sister chromatid exchange test O* 1986 (OECD)
In vitro unscheduled DNA synthesis test O* 1986 (OECD)






Bacterial reverse mutation (Ames) test O* 1997 (OECD)




O* 2006 (ESAC) Submitted to EMA
Immunotoxicity/Skin Sensitization
Local lymph node assay (LLNA) O O 1999 (ICCVAM) 2002 (OECD)
Reduced LLNA: rLLNA O O 2007 (ESAC) 2010 (OECD)
Nonradiolabelled LLNA: DA O O 2008 (JaCVAM) 2010 (OECD)
Nonradiolabelled LLNA: BrdU-ELISA O O 2009 (ICCVAM) 2010 (OECD)
LLNA for potency characterization O O 2011 (ICCVAM) 2009 (UN GHS)
Phototoxicity
3T3 Neutral Red Uptake Phototoxicity
Test
O 1997 (ESAC) 2004 (OECD)
3T3 NRU Phototoxicity Test: Application
to UV filter chemicals
O 1998 (ESAC) 2004 (OECD)
Pyrogenicity
Human whole blood IL-1 O* 2006 (ESAC) EMA
Human whole blood IL-6 O* 2006 (ESAC) EMA
Human cryopreserved whole blood IL-1 O* 2006 (ESAC) EMA
PBMC IL-6 O* 2006 (ESAC) EMA
MM6 IL-6 O* 2006 (ESAC) EMA
Limulus amebocyte lysate (LAL) test O* European Pharmacopeia
Reproductive & Developmental Toxicity
Embryonic stem cell test for
embryotoxicity




















































































Replacementa Reduction Refinement Validation Status Regulatory Acceptance
Micromass embryotoxicity assay O* 2002 (ESAC)





EpiSkins human skin model O 1998 (ESAC) 2004 (OECD)
Rat skin transcutaneous electrical
resistance (TER) assay
O 1998 (ESAC) 2004 (OECD)
Corrositexs noncellular membrane O 1999 (ICCVAM) 2006 (OECD)
EpiDermt human skin model O 2000 (ESAC) 2004 (OECD)
SkinEthict human skin model O 2006 (ESAC) 2004 (OECD)
Vitrolife-Skin human reconstructed
epidermis
O 2008 (JaCVAM) 2004 (OECD)
EST-1000 human reconstructed epidermis O 2009 (ESAC) 2004 (OECD)
Skin Irritation
EpiSkins skin irritation test (with MTT
reduction)
O 2007 (ESAC) 2010 (OECD)
EpiDermt skin irritation test (with
MTT reduction)
O 2007 (ESAC) EU test method B.46 in
COM regulation 440/
2008/EC
EpiDermt SIT model (EPI-200) O 2008 (ESAC) 2010 (OECD)
SkinEthic RHE model O 2008 (ESAC) 2010 (OECD)
aWhether or not a test method is a full or partial replacement is not always unambiguous.
bThe upper threshold concentration step-down approach was issued as a guidance document because consensus could not be reached.
cThe in vitro skin absorption methods do not apply to mixtures/formulations.
Abbreviations: EMA: European Medicines Agency; EPA: US Environmental Protection Agency; ESAC: ECVAM Scientific Advisory Committee; GHS:
Globally Harmonized System of Classification and Labelling of Chemicals; ICCVAM: US Interagency Coordinating Committee on the Validation of Alternative
Methods; JaCVAM: Japanese Center for the Validation of Alternative Methods; OECD: Organisation for Economic Co-operation and Development.





































































(Table 1.5) and the development of the principles and procedures of validation
and regulatory acceptance (see Section 1.4.3). Second, the bulk of this effort has
been invested in replacement alternatives (full or partial), with acute systemic
toxicity and skin sensitization being notable exceptions. This activity has been
driven, in part, by the ban on animal testing for cosmetic ingredients, pursuant
to the European Cosmetics Directive.
Much of what we might term ‘‘toxicological space’’ has been touched by
alternative methods. This is especially true for acute toxicity endpoints, where
replacement alternatives have become available for skin penetration, skin
corrosion, skin irritation, and phototoxicity. However, the challenge of re-
placing animal use for chronic endpoints is much more formidable.24 One
prominent effort addressing the challenge of alternatives to chronic toxicity
testing is the SEURAT program, a multi-million Euro partnership between the
cosmetics industry and the European Union.e A roadmap for replacing animals
in chronic and systemic toxicity testing has been published recently.25
Of course, validation and regulatory acceptance of new methods do not
necessarily ensure full implementation of those methods in all cases, so the
degree of implementation and any barriers to implementation would need to be
addressed in a more definitive analysis of the impact of alternative methods on
toxicology.43–45
What would Russell and Burch themselves have made of the record of
achievement as reflected in Table 1.7? Rex Burch died in 1996 and William
Russell in 2006, but their writings and statements towards the end of their lives
suggest their pride in what their pioneering book set in motion.3,46 Of course,
much remains to be done, with formidable challenges ahead (see Section 1.6).
1.5.2 Historical Trends in Animal Use in Toxicology
Both reduction and replacement alternatives should result in fewer animals
being used. However, animal use in any scientific field can be influenced by a
host of other factors, including whether overall activity in that field is ex-
panding or contracting over time. An expanding field could mask any gains
from reduction and replacement alternatives, whereas a field in decline could
exaggerate the perceived impact of such alternatives.
Given the trends we have seen in the history of the 3Rs in toxicology, we
would expect the largest impact of the 3Rs on animal use in this field to be
apparent since the beginning of the 2000s, following the establishment of the
process of validation and of the validation centers themselves, as well as the
actual validation and regulatory acceptance of individual tests (see Sections
1.4.3 and 1.5.1). Even prior to the validation and regulatory acceptance of
alternatives, a general sensitivity to animal welfare and the 3Rs approach may
have lead to greater scrutiny of animal use in toxicology and subsequent re-
ductions in animal numbers, especially in pre-regulatory toxicology. On the
ehttp://www.seurat-1.eu





























































other hand, animal testing inevitably increases over the short term when new
testing programs are launched (e.g., REACH), new endpoints are developed
(e.g., endocrine disruption), and new types of chemicals are commercialized
(e.g., nanoparticles).
Reports from several countries provide evidence that overall animal use (for
any purpose, not just for toxicology) declined during the last quarter of the 20th
century (Andrew Rowan, personal communication). To analyze international
trends in animal use in toxicology, data need to be gathered in a way that allows
comparison across countries. The best source for such data comes from the EU.
Consistent statistics on animal use in toxicology began to be aggregated across
EU member states (nations) in 1999, and since then have been compiled every
three years, with 2008 the most recent compilation. These statistics do not allow
us to assess the impact of early 3Rs activity, but they do cover the years when
we would expect to see an impact from the development and validation of al-
ternatives (see Sections 1.4.3 and 1.5.1).
We combined the statistics on numbers of animals used for toxicology with
statistics on numbers of animals used for the production and quality control of
products and devices for human medicine, dentistry, and veterinary medicine.
We controlled for the fact that the number of EU member states has grown
over the years in question by assessing data from the five EU countries that use
the most animals overall: France, Germany, the United Kingdom (UK), Italy,
and Belgium. These five countries, when taken together, account on average for
80% of the total animal use in toxicology by the EU, and each has used more
than 200,000 animals for toxicity testing in at least one reporting year. More-
over, we normalized each country’s numbers, setting the total animal use for
each country during its first reporting year as a baseline (100%), in order to
more easily compare trends across countries. Thus, we can see the relative
change in animal use in each country since 1999 (2002 for Germany).
We found that there is little consistency in the levels of animal use in tox-
icology across countries over the decade in question (Figure 1.6). Italy’s
numbers consistently (and dramatically) dropped, Belgium’s numbers steadily
rose, Germany’s numbers remained fairly steady, and France and the UK
showed more complicated patterns. France’s numbers increased initially and
then ended with a substantial decline, whereas animal use in the UK declined
for many years but ended with a substantial increase from 2005 to 2008.
Looking across these five countries as a whole, however, the overall trend is
one of modest decline, with the number of animals used for toxicity testing in
2008 totaling 87% of those used in 2002. This recent decline could be evidence
that, notwithstanding the influence of various factors tending to drive up ani-
mal numbers in toxicology (e.g., REACH), the 3Rs are actually bringing ani-
mal numbers down. This remains speculative in the absence of further evidence.
Yet even in the absence of such information, it is clear that much remains to
be done in applying the 3Rs in toxicology. Although no precise estimates are
available, animal use in toxicology worldwide is still counted in the millions of
animals. In light of the unfulfilled potential of 3Rs activity within toxicology,































































In the decades following publication of Russell and Burch’s The Principles of
Humane Experimental Technique in 1959, the emerging 3Rs community devoted
much of its energy to the field of toxicology. An infrastructure for making pro-
gress was slowly and steadily developed. This included alternatives-based or-
ganizations and centers, journals, websites, laws, conferences, and other activity.
The 3Rs community also spearheaded the development of the scientific standards
(e.g., validation) and worked with fellow toxicologists and others to improve the
techniques (e.g., tissue culture) that facilitated progress. The result has been a
progressive chipping away at traditional animal-based methods.
The publication of the NRC report on Toxicity Testing in the 21st Century in
2007 created a new point of reference for the 3Rs community, suggesting a new
approach to replacing animal use in toxicology. Within the mainstream
Figure 1.6 Animal use in toxicity testing in the European Union (EU) (1999–2008),
based on European Commission reports to Parliament and working
documents on the Statistics on the Number of Animals Used for Experi-
mental and Other Scientific Purposes in the Member States of the Euro-
pean Union. Data shown only for those member countries using4200,000
animals in toxicity testing in a given year (France, Germany, United
Kingdom, Italy, Belgium), which collectively account for approximately
80% of the total number of animals used in toxicity testing in the EU. No
data are shown for Germany in 1999 because data were compiled differ-
ently that year, and therefore no data are shown for EU5 (the combined
animal use from the 5 countries listed) for 1999. For ease of comparison,
data are normalized such that animal use for the first reporting year is set
to 100% for each country, and animal use in other years is expressed as a
percentage of that year. Data tallied from boxes 2.4 (production and
quality control of products and devices for human medicine and den-
tistry), 2.5 (production and quality control of products and devices for
veterinary medicine), and 2.6 (toxicological and other safety evaluations,
including safety evaluations of products and devices for human medicine
and dentistry and for veterinary medicine) of the reports.





























































toxicology and public health communities, the NRC report engendered con-
siderable enthusiasm for modernizing toxicology. Leading federal scientists
began predicting a paradigm shift from in vivo- to in vitro-based methods (see
Section 1.1). Many in the alternatives community have been seeking to facili-
tate this long-term effort.39,47 As pathway-based approaches are further elab-
orated, they can be incorporated into ongoing 3Rs efforts.
However, implementing pathway-based approaches to predictive toxicology
raises a host of formidable challenges.48 These include developing fit-
for-purpose assays to monitor pathway perturbations, distinguishing adverse
responses in these assays from homeostatic responses,49 accounting for me-
tabolism of the parent compound, and shifting to a safety-based risk assess-
ment paradigm, rather than one based on hazard.10
21st century toxicology efforts have the long-term goal of providing a new
paradigm for safety assessment; however, for the time being, most of these
efforts are being harnessed to predict the outcomes of traditional animal test-
ing. Consequently, the first applications are supplementing rather than sup-
planting the current paradigm. We need to accelerate the transition to the new
paradigm, based on human biology.47
20th century validation processes will need to be adapted to 21st century tox-
icology.50 There are many reasons why the existing validation processes should not
be deployed as is. First, pathway-based methods are not intended as one-to-one
replacements of animal-based tests; multiple pathway-based assays, perhaps num-
bering in the hundreds, will be used to make predictions about individual chemicals.
Second, pathway-based methods ultimately will be called on to mimic human
biology, rather than to predict the results of animal testing – the standard assurance
of relevance. Third, according to the NRC framework, pathway-based assays will
be used to predict regions of safe exposures, rather than predict specific toxicities.
And fourth, the science and technology of 21st century toxicology are changing too
rapidly for an evaluation process that takes a year or more to complete.
Most of the existing validation principles may carry over and transcend a
paradigm shift in testing, but the prevailing validation procedures will need to
be translated to accommodate these new realities. Validation procedures must
also somehow be speeded up to accommodate the new pace of change and be
flexible enough to accommodate an ideal of continual improvement in testing
methods. Some rethinking of validation has begun to occur in this context. 50–52
And finally, perhaps the biggest real-world challenge to further progress on
the 3Rs in toxicology is tackling systemic and chronic toxicity testing. Some
large-scale programs in Europe have been seeking to address elements of this
challenge, such as REPROTECT (reproductive toxicity)53 and SEURAT-1
(repeat dose systemic toxicity testing),54 with coordination and guidance pro-
vided by the AXLR8 program.f In the U.S., high-throughput testing is being
used to identify biological signatures of chronic, systemic endpoints, such as in































































strategies involving multiple types of testing and approaches (e.g., pathway-
based testing, high-throughput testing, toxicogenomics, organ-on-a-chip plat-
forms, virtual organs) will play a role. Also critical will be a realistic assessment
of the limitations (as well as the strengths) of the current animal-based assays.25
1.7 Conclusions
Progress on the 3Rs has been driven by a dual concern for animal welfare and
scientific advancement. Much of this progress to date, especially in toxicology,
can be attributed to the efforts of those who would identify themselves as part
of the 3Rs or alternatives community and can be traced back in time to the
pioneering efforts of William Russell and Rex Burch. What is especially ex-
citing about the current era is that the 3Rs community is now working in
parallel with a vanguard in the toxicology community seeking to usher in new
approaches. Time will tell whether we are at the threshold of alternative ap-
proaches becoming the mainstream of the new toxicology.34,39
Appendix A: Citation Search Strategies
We searched Web of Science, BIOSIS, and SCOPUS databases for citations to
Russell and Burch’s The Principles of Humane Experimental Technique, whe-
ther in its original edition4 or its 1992 reprint,30 and the NRC’s Toxicity Testing
in the 21st Century: A Vision and a Strategy9 from the year of their respective
publication to 2011, the latest year for which complete records were available.
In addition, we searched SciSearch and Google Scholar for citations to The
Principles up to and including the year 1999 to help compensate for the likely
under-representation of papers and book citations during these years in the
main databases.
For Web of Science, BIOSIS, SCOPUS, and SciSearch, we limited our results
to publications related to toxicity testing by using the appropriate database
subject/research area limits. In some cases, databases grouped toxicology and
pharmacology together as one subject area. In others, the subject areas were
distinct and pharmacology was included only if it was defined to include topics
of relevance to toxicity testing. For the Google Scholar search, no subject area
limits were available, so we curated our results to remove any publications not
clearly related to toxicology.
We adopted a search strategy that would be robust enough to capture
variations in how the author names and titles were entered into the databases,
including misspellings. Searches were conducted October/November 2012.
Databases
1 Web of Science
According to its website, ‘‘Web of Sciences provides access to citation data-
bases with multidisciplinary content including Open Access journals and over





























































150,000 conference proceedings. It includes current and retrospective coverage
in the sciences, social sciences, arts, and humanities, with coverage to 1900.’’g
The relevant subject filters were ‘‘Toxicology’’ and ‘‘Pharmacology & Phar-
macy.’’ ‘‘Toxicology’’ covers ‘‘resources that focus on the identification, bio-
chemistry, and effects of harmful substances, including the side effects of drugs,
in animals, humans, and the environment.’’ ‘‘Pharmacology & Pharmacy’’
covers ‘‘resources on the discovery and testing of bioactive substances, in-
cluding animal research, clinical experience, delivery systems, and dispensing of
drugs. This category also includes resources on the biochemistry, metabolism,
and toxic or adverse effects of drugs.’’h
2 BIOSIS
According to its website, BIOSIS Citation Index ‘‘covers all major areas in the
life sciences, with broad coverage in molecular and cell biology, pharmacology,
endocrinology, genetics, neurosciences, infectious diseases, ecology and orga-
nismal biology. It provides access to over 22million records from journals,
books, reports, meetings, and U.S. patents dating 1926 or later.’’i Subjects are
defined in the same way as in Web of Science (above).
3 SCOPUS
According to SCOPUS, the database ‘‘is an abstract and citation database of
peer-reviewed literature with tools that track, analyze and visualize research.
Scopus includes over 20,500 titles from 5,000 publishers worldwide, 49million
records (78% with abstracts) and over 5.3million conference papers.’’j The
relevant subject filter in SCOPUS is ‘‘Pharmacology, Toxicology and
Pharmaceutics’’ (no further description available).
4 SciSearch (Accessed via DialogWeb)
According to DialogWeb, SciSearch is ‘‘an international, multidisciplinary
index to the literature of science, technology, biomedicine, and related discip-
lines produced by Thomson Scientific. SciSearch contains all of the records
published in the Science Citation Indexs (SCIs), plus additional records in
engineering technology, physical sciences, agriculture, biology, environmental
sciences, clinical medicine, and the life sciences. SciSearch indexes all significant
items (articles, review papers, meeting abstracts, letters, editorials, book re-
views, correction notices, etc.) from more than 6,100 international scientific and





































































According to Google, ‘‘Google Scholar includes scholarly articles from a wide
variety of sources in all fields of research, all languages, all countries, and over
all time periods. Google Scholar searches across many disciplines and sources:
articles, theses, books, abstracts and court opinions, from academic publishers,
professional societies, online repositories, universities and other web sites. To
be considered for inclusion, website content needs to meet two basic criteria:
1. Must include scholarly articles – journal papers, conference papers, technical
reports, or their drafts, dissertations, pre-prints, post-prints, or abstracts . . . .
2. Must show abstracts – websites must make either the full text of the articles
or their complete author-written abstracts freely available and easy to see when
users click on URLs in Google search results . . . .’’l
Search Terms
1 Web of Science
We selected the ‘‘Web of Science’’ tab and then the ‘‘Cited Reference’’ tab. To
retrieve citations to The Principles, we entered:
‘‘Russel*, W*’’ in Cited Author AND
‘‘Burch, R*’’ in Cited Author AND
‘‘1959–2011’’ in Cited Year(s)
This produced 13 entries, of which we selected the 11 that were relevant to our
search and clicked ‘‘Finish Search.’’ We refined the results by Research Area
(on the left-hand side), selecting both Toxicology and Pharmacology/Pharmacy.
For citations to Toxicity Testing in the 21st Century, we located three entries,
and the results were refined by Research Area to both Toxicology and
Pharmacology/Pharmacy.
2 BIOSIS
We selected the ‘‘Select a Database’’ tab, then selected ‘‘BIOSIS Citation
Index,’’ and from there selected the ‘‘Cited Reference’’ tab. We entered the
same search terms as for Web of Science (above).
This produced 15 entries, of which we selected the 13 that were relevant to
our search and clicked ‘‘Finish Search.’’ We refined the results by Research
Area (on the left-hand side), selecting both Toxicology and Pharmacology/
Pharmacy.
For citations to Toxicity Testing in the 21st Century, we located three entries,
and the results were refined by Research Area to both Toxicology and
Pharmacology/Pharmacy.
lhttp://scholar.google.com/intl/en-US/scholar/help.html#coverage






























































To find citations, we first needed to enter a publication known to cite the work
in question, then locate the reference in that publication’s entry. Next to the
reference, there is text stating ‘‘Cited X times,’’ with a link to the citations.
Doing this, we were able to retrieve citations to both editions of The Principles
and to the Toxicity Testing in the 21st Century report. SCOPUS does not have
the same complication with variations of author name(s) and title as do Web of
Science and BIOSIS.
4 SciSearch
We used SciSearch only for The Principles and entered the following
search terms:
S1 CR¼RUSSELL WMS, 1959?
S2 S1 AND PY¼ 197?:1999
S3 S2 AND (TOX? OR TEST?)
And:
S1 CR¼RUSSELL W??, 1992?
S2 S1 AND PY¼ 1992–1999
S3 S2 AND (TOXIC? OR TEST?)
5 Google Scholar: http://scholar.google.com
We searched for ‘‘Principles of Humane Experimental Technique,’’ and then
selected the top result, which was for ‘‘The principles of humane experimental
technique; WMS Russell, RL Burch, CW Hume  1959 - altweb.jhsph.edu.’’
Several other entries were listed for the book, but these had relatively few
citations (generally less than 15 each), compared to more than 1400 citations
for the entry we selected. As the database does not allow results to be restricted
to certain research or subject areas, citations through 1999 were hand-curated
to remove any not related to toxicology or pharmacology.
Limitations
Not all journal articles, books, or other documents will be indexed by the
databases we used, and coverage is typically weaker prior to the early- to mid-
1990s. In addition, some publications with relevance to toxicology may not be
indexed under the Toxicology or Pharmacology research areas. While database
indexers do their best to apply all relevant terms, it may have been particularly






























































years of these fields, but also perhaps in more recent years as new specialties
come to be identified as the primary focus.
To try to compensate for some of these factors, we included additional
databases in our search for citations to The Principles prior to 2000.
(There is likely to be greater overlap among the databases in more recent years.)
While inclusion of these databases increased the absolute number of citations we
were able to find, it did not significantly alter the general trend (data not shown).
Therefore, we expect that the total number of citations is likely higher
than what we found, even with enhancement for the years prior to 2000, but
the overall trend should remain valid. For The Principles, we see a low number of
citations prior to 1980, a growth through the 1980s and 1990s, and a significant
uptick starting in the mid-2000s. For Toxicity Testing in the 21st Century, we see
an immediate uptake equaling, if not exceeding, reference to The Principles.
It is possible that the trend for The Principles largely mirrors the trajectory of
toxicology publications in general. Advances in computer and internet tech-
nologies over the past one or two decades, for example, have had a tremendous
impact on the number of and ease with which journals and papers can be
published and indexed. As more papers get published, the number of papers
citing The Principles has increased, but we do not know if the relative pro-
portion of papers citing The Principles has decreased, increased, or remained
steady. Notwithstanding this caveat, the trend in total number of citations
could have looked very different, and our analysis shows a clear rise in influence
of Russell and Burch’s pioneering book during the last quarter of the 20th
century and an enduring legacy into the 21st.
Appendix B: Literature Search Strategies
We conducted formal literature searches using Ovid Medline and Embase data-
bases to identify a comprehensive, though not exhaustive, universe of 3Rs-related
papers. Papers were considered to be related to the 3Rs if they used common 3Rs
terminology or related synonyms, or if they were indexed as such by the databases.
Several different search strings (queries) were devised to capture papers as com-
prehensively as possible while minimizing the number of irrelevant papers also
captured. We did not, however, remove these ‘‘false positives’’ from our data set
(of over 3000 records), which we estimated represented only 5–10% of our total.
We limited our results to those papers related to the field of toxicology, but
did not include the field of pharmacology because these databases defined the
field too broadly for our purposes. Instead, we included searches for vaccine
safety and potency testing, which tended to fall in pharmacology rather than
toxicology but are nonetheless related to toxicity testing.
We then categorized papers based on the occurrence of selected terms with 3Rs
significance in the title, abstract, or key word fields of their database entries.
Papers could be included in multiple categories if they contained more than one
of the selected terms. While we selected a representative sample of important
3Rs-related approaches or concepts, such as humane endpoints and validation,
no attempt was made to be exhaustive in the topics covered.
Searches were conducted during October 2012.































































According to Ovid, Ovid Medline is updated daily and ‘‘provides access to the
latest bibliographic citations and author abstracts from more than 5,500 bio-
medicine and life sciences journals in nearly 40 languages (60 languages for older
journals). English abstracts are included in more than 80% of the records.’’m
The ‘‘Toxicology Limit’’ was based on PubMed’s Toxicology subset limit.n
2 Embase
According to Embase, the database ‘‘covers international biomedical literature
from 1947 to the present day. The database contains over 25million indexed
records and more than 7,600 currently indexed peer-reviewed journals. All
MEDLINE records produced by the National Library of Medicine (NLM) are
included, as well over 5million records not covered on MEDLINE.’’o
Embase uses ‘‘Areas of Focus’’ filters, of which the relevant one for our
purposes was ‘‘Toxicology and Drug Dependence.’’ According to Embase, this
area ‘‘covers topics relating to toxic mechanisms and effects of both medicinal
and non-medicinal substances. Included in this coverage are: Abuse of drugs,
alcohol and organic solvents; Experimental pharmacology of addiction; Pre-
dictive toxicology. Coverage: records from 1983 to present.’’p The ‘‘Pharma-




The following list of animal terms (‘‘[list of animals]’’) appeared in most of our
searches:
(animal$1 or rat or rats or mouse or mice or dog$1 or cat$1 or hamster$ or
gerbil$ or ‘‘guinea pig$1’’ or monkey$1 or primate$1 or rodent$1 or rabbit$1 or
bird$1 or fish$2 or zebrafish or chicken$1)
Indexing terms:
1) exp ‘‘Animal Use Alternatives’’/ and (test or tests or testing or
toxic$).ab,ti,jw.
Alternatives to the use of animals:
2) ((alternative$1 adj5 (‘‘use’’ or ‘‘uses’’ or ‘‘using’’ or test or tests or
testing)) and ((‘‘use’’ or ‘‘uses’’ or ‘‘using’’ or test or tests or testing) adj3
([list of animals]))).mp.
mhttp://www.ovid.com/webapp/wcs/stores/servlet/

































































3) ((alternative$1 adj5 (‘‘use’’ or ‘‘uses’’ or ‘‘using’’ or test or tests or
testing)) and ((‘‘use’’ or ‘‘uses’’ or ‘‘using’’ or test or tests or testing) adj3
([list of animals]))).mp. AND toxic$.jw.
3Rs:
4) (3Rs or ‘‘Three Rs’’ or ‘‘Three R’’ or ‘‘3R principle’’ or ‘‘3R principles’’
or ‘‘3R approach’’ or ‘‘3R approaches’’ or ‘‘3R method’’ or ‘‘3R
methods’’ or ‘‘3R concept’’ or ‘‘3R concepts’’ or ‘‘3R strategy’’ or ‘‘3R
strategies’’ or (3R adj4 (alternative or alternatives))).mp.
Replace, reduce, and refine:
5) (Replac$ and reduc$ and refin$).mp.
Animal Refinement:
6) (([list of animals]) adj5 refin$).ti,ab. and (alternative or alternatives or
test or testing).mp.
Minimize or eliminate pain or distress:
7) ([list of animals]).ti,ab. and ((minim$ or eliminat$) adj4 (pain or dis-
tress)).ti,ab. and (alternative or alternatives or testing).mp.
Reduce, alleviate, or lessen pain or distress:
8) ([list of animals]).ab,ti. and ((reduc$ or alleviat$ or less$) adj4 (pain or
distress)).ab,ti. and ((toxic$ and chemical$) or (toxic$ adj3 test$) or
((alternative or alternatives) and toxic$)).ab,ti
Reduce, alleviate, lessen, minimize, eliminate, or decrease suffering:
9) ([list of animals]).ab,ti. and ((reduc$ or alleviat$ or less$ or minim$ or
eliminat$ or decreas$) adj4 suffer$).ab,ti. and (alternative or alternatives
or test or testing).ab,ti.
Animal replacement:
10) ((([list of animals]) adj5 replac$) and (alternative or alternatives)).mp.
11) ([list of animals]).ab,ti. and (replace and (alternative or
alternatives)).mp.
Animal reduction:
Reduce the number of animals/Number of animals reduced:
12) (((reduc$ or minim$ or fewer) adj4 number$) and (number$ adj3 ([list of
animals])) and (alternative or alternatives or testing or toxicity)).ti,ab.
Reduce the use of animals/Use of animals reduced/Animal use reduced:
13) (((reduc$ or decreas$ or minim$ or eliminat$ or fewer) adj6 (‘‘use’’ or
‘‘uses’’ or ‘‘used’’)) and ((‘‘use’’ or ‘‘uses’’ or ‘‘used’’) adj6 ([list of ani-
mals])) and (([list of animals]) adj6 (reduc$ or decreas$ or minim$ or
eliminat$ or fewer)) and (alternative or alternatives or testing or
toxicity)).ti,ab.
Reduce animal testing/Animal testing reduced:
14) (((reduc$ or decreas$ or minim$ or eliminat$) adj5 ([list of animals]))
and (([list of animals]) adj1 (test or tests or testing)) and ((reduc$ or
decreas$ or minim$ or eliminat$) adj4 (test or tests or testing)) and
(alternative or alternatives or testing or toxicity)).ti,ab.
Refine and Reduce:
15) ((refin$ adj6 reduc$) and (alternative or alternatives or test$ or
toxic$)).ti,ab.





























































Vaccine Safety and Potency Testing:
16) ((vaccine or vaccines) and (safety test$ or potency test$ or batch test$ or
quality control) and (alternative or alternatives) and (in vitro or in vivo
or ([list of animals]))).ti,ab.
17) Combine 1-2 and 4-16 with OR.
18) Limit 17 to toxicology.
19) Combine 3 and 18 with OR.
Embase
The following list of animal terms (‘‘[list of animals]’’) appeared in most of our
searches:
(animal OR animals OR rat OR rats OR mouse OR mice OR dog OR dogs
OR cat OR cats OR hamster* OR gerbil* OR ‘‘guinea pig’’ OR ‘‘guinea pigs’’
OR monkey* OR primate* OR rodent OR rodents OR rabbit* OR bird* OR
fish* OR zebrafish OR chicken*)
Indexing Terms:
1) ‘‘animal testing alternative’’/exp AND (test OR tests OR testing OR
toxic*):ab,ti
Alternatives to the use of animals:
2) ((Alternative or alternatives) NEAR/5 (use or uses or using or test or
tests or testing)):ti,ab AND ((use or uses or using or test or tests or
testing) NEAR/3 ([list of animals])):ti,ab AND [toxicology and drug
dependence]/lim
3Rs:
3) (3Rs OR ‘‘Three Rs’’ OR ‘‘Three R’’ or ‘‘3R principle’’ or ‘‘3R prin-
ciples’’ or ‘‘3R approach’’ or ‘‘3R approaches’’ or ‘‘3R method’’ or ‘‘3R
methods’’ or ‘‘3R concept’’ or ‘‘3R concepts’’ or ‘‘3R strategy’’ or ‘‘3R
strategies’’ or 3R NEAR/3 (alternative or alternatives)) AND [toxicol-
ogy and drug dependence]/lim
Replace, reduce, and refine:
4) Replac* AND reduc* AND refin* AND [toxicology and drug depend-
ence]/lim
Animal Refinement:
5) (([List of animals]) NEAR/5 refin*):ti,ab AND (alternative or alter-
natives or test or testing) AND [toxicology and drug dependence]/lim
Minimize or eliminate pain or distress:
6) ([List of Animals]):ti,ab,de AND ((minim* OR eliminat*) NEAR/4
(pain or distress)):ab,ti AND (alternative OR alternatives OR test OR
testing) AND [toxicology and drug dependence]/lim
Reduce, alleviate, or lessen pain or distress:
7) ([List of Animals]):ti,ab,de AND ((reduc* OR alleviat* OR less*)
NEAR/4 (pain or distress)):ab,ti AND ((toxic* AND chemical*) OR
(toxic* NEAR/3 test*) OR (alternative OR alternatives AND tox-






























































Reduce, alleviate, lessen, minimize, eliminate, or decrease suffering:
8) ([List of Animals]):ti,ab,de AND ((reduc* OR alleviat* OR less* OR
minim* OR eliminat* OR decreas*) NEAR/4 suffer*):ab,ti AND (al-
ternative OR alternatives OR test OR testing):ab,ti AND [toxicology
and drug dependence]/lim
Animal Replacement:
9) (([List of animals]) NEAR/5 replac*) AND (alternative or alternatives)
AND [toxicology and drug dependence]/lim
10) ([List of animals]):ti,ab,de AND replace AND (alternative or alter-
natives) AND [toxicology and drug dependence]/lim
Animal Reduction:
Reduce the number of animals/Number of animals reduced:
11) ((reduc* OR minim* OR fewer) NEAR/4 number* AND number*
NEAR/3 ([list of animals])):ti,ab AND (alternative or alternatives or
testing or toxicity):ti,ab AND [toxicology and drug dependence]/lim
Reduce the use of animals/Use of animals reduced/Animal use reduced:
12) (((reduc* or decreas* or minim* or eliminat* or fewer) NEAR/6 (use or
uses or used)) AND ((use or uses or used) NEAR/6 ([list of animals]))
AND (([list of animals]) NEAR/6 (reduc* or decreas* or minim* or
eliminat* or fewer)) AND (alternative or alternatives or testing or tox-
icity)):ti:ab AND [toxicology and drug dependence]/lim
Reduce animal testing/Animal testing reduced:
13) ((reduc* or decreas* or minim* or eliminat*) NEAR/5 ([list of animals])):
ti,ab AND (([list of animals]) NEAR/1 (test or tests or testing)):ti,ab AND
((reduc* or decreas* or minim* or eliminat*) NEAR/4 (test or tests or
testing)):ti,ab AND (alternative or alternatives or testing or toxicity):ti:ab
AND [toxicology and drug dependence]/lim
Refine and Reduce:
14) (refin* NEAR/6 reduc*):ti,ab,de AND (alternative or alternatives or
test* or toxic*) AND [toxicology and drug dependence]/lim
Vaccine Safety and Potency Testing:
15) ((vaccine OR vaccines) AND ((safety NEXT/1 test*) OR (potency
NEXT/1 test*) OR (batch NEXT/1 test*) OR ‘‘quality control’’) AND
(alternative OR alternatives) AND (‘‘in vitro’’ OR ‘‘in vivo’’ OR ([list of
animals]))):ab,ti
16) Combine #1-#15 with OR.
Categorization
We parsed our universe of 3Rs-related papers into various categories to assess
the frequency of occurrence of select key topics. We assigned a paper to any
categories for which the associated term(s) appeared in the abstract, title, or key
word fields of the paper’s database entry.
 Replacement: ‘‘replac’’
 Reduction: ‘‘reduc’’






























































 In vitro/Cell culture/Tissue culture: ‘‘in vitro,’’ ‘‘cell culture’’ and/or
‘‘tissue culture’’
 Validation: ‘‘validat’’
 In silico/(Q)SAR: ‘‘in silico,’’ ‘‘SAR,’’ ‘‘structure activity relation,’’ and/or
‘‘structure-activity relation’’
 (Integrated) testing strategy: ‘‘testing strateg’’
 Humane endpoint: ‘‘humane endpoint’’
 Enrichment: ‘‘enrichment’’
Limitations
In addition to those limitations identified for the citation search for The
Principles (Appendix A), which apply equally as well to the literature search for
3Rs papers, additional factors must be considered in interpreting these results.
Our search could only retrieve those papers employing our specific search
terms and formulations. Some proportion of 3Rs-related papers, however, may
use terminology that is less specific and therefore not easily identified by
searches designed to minimize false positives. Even the main 3Rs terms ‘‘re-
place,’’ ‘‘reduce,’’ and ‘‘refine’’ are relatively non-specific, thereby increasing
the difficulty of locating papers discussing these topics.
Relatedly, papers may address 3Rs concepts without using 3Rs-specific ter-
minology or without being framed as such. The lack of uniform publication
requirements to explicitly describe the 3Rs implications of a given work ex-
acerbates this difficulty. The growing number of 3Rs-related papers may partly
reflect the increasing penetration of 3Rs terminology, however, and this in itself
would be an indicator of the growing influence and sophistication of 3Rs ideas.
Even if papers used the 3Rs terminology employed in our search, they may
not have been identified if the search terms did not appear in the title, abstract,
or key words. Also, many early papers are not indexed in the databases with
their abstracts, so only their titles are amenable to searching. This contributes
to our underestimate of 3Rs papers prior to the 1990s. Database indexing
terms, such as Medline/Pubmed’s ‘‘animal testing alternative,’’ are also not
entirely reliable, resulting in many alternatives papers not being indexed as
such. In some cases, though, the term may be applied to papers that are not
clearly discussing the 3Rs, contributing to our false positives.
With regard to categorizing papers based on the 3Rs concept they address
(e.g., replacement, reduction, refinement, validation, etc.), our search does not
retrieve papers addressing these concepts if they are not indexed as toxicology
papers. Thus, work on topics like refinement, humane endpoints, and enrich-
ment, which is more likely to be general to animal research rather than specific
to toxicology, would be underrepresented in our search even though such work
is of use to toxicologists.
Further, papers were categorized based simply on the occurrence of selected
terms. It is possible that some papers may use a term but not be about that






























































refinement’’ to introduce the concept of the 3Rs, but may actually only address
one of the Rs. Such papers, however, would get categorized under each of
the Rs.
Despite these limitations, many of which are inherent to database searching,
our analyses provide useful insight into the penetrance and explicit use of 3Rs
terminology and concepts in toxicology over time.
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